Kerri Cravey
Nurse Practitioner · Huntsville, TXNPI 1578511275
Payments from drug & device makers
Across 130 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$478
- Amgen$453
- Lilly USA, LLC$283
- Pfizer$227
- AbbVie$138
- Novo Nordisk$129
- plus $922 from 19 others
What the payments were for
- Food & beverage$2,61699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $478 |
| Amgen | 14 | $453 |
| Lilly USA, LLC | 20 | $283 |
| Pfizer | 10 | $227 |
| AbbVie | 6 | $138 |
| Novo Nordisk | 7 | $129 |
| Dexcom, Inc. | 6 | $114 |
| Bayer | 5 | $113 |
| Exact Sciences | 6 | $97 |
| Astellas Pharma US Inc | 4 | $83 |
| Abbott | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Evofem Biosciences, Inc. | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Antares Pharma, Inc. | 2 | $33 |
| Cranial Technologies, Inc | 2 | $33 |
| Merck | 2 | $28 |
| Tolmar, Inc. | 2 | $28 |
| Coopersurgical, Inc. | 1 | $25 |
| Biogen | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$101
How this compares
$2,630 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $27,741 |
| JardianceEmpagliflozin | 37 | $26,917 |
| MounjaroTirzepatide | 16 | $16,344 |
| TrulicityDulaglutide | 13 | $12,438 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,305 |
| Duloxetine Hcl | 34 | $1,041 |
| Estradiol | 15 | $840 |
| Atorvastatin Calcium | 85 | $629 |
| Levothyroxine Sodium | 63 | $542 |
| Losartan Potassium | 40 | $518 |
| Metoprolol Succinate | 26 | $469 |
| Buspirone Hcl | 37 | $463 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $458 |
| Gabapentin | 35 | $421 |
| Ondansetron OdtOndansetron | 33 | $419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $283 | $28,78229 claims |
| Novo NordiskOzempic | $129 | $27,74119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Huntsville
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
- Onna FeuchterSouthlake$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.